Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.58 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15780394 | 1.00 | LTA4H (0.58) | LTA4HFUCA1KDM1AMAOACD274 | |
| SCHEMBL28709021 | 1.00 | LTA4H (0.58) | LTA4HFUCA1KDM1AMAOACD274 | |
| SCHEMBL15921601 | 1.00 | LTA4H (0.58) | LTA4HFUCA1KDM1AMAOACD274 | |
| SCHEMBL1755583 | 1.00 | LTA4H (0.58) | LTA4HFUCA1KDM1AMAOACD274 | |
| SCHEMBL1361936 | 1.00 | LTA4H (0.58) | LTA4HFUCA1KDM1AMAOACD274 | |
| SCHEMBL14001426 | 1.00 | LTA4H (0.58) | LTA4HFUCA1KDM1AMAOACD274 | |
| SCHEMBL697761 | 1.00 | LTA4H (0.58) | LTA4HFUCA1KDM1AMAOACD274 | |
| Hydrochloric Acid SCHEMBL3337665 | 0.98 | LTA4H (0.56) | LTA4HFUCA1KDM1AMAOACD274 | |
| Hydrochloric Acid SCHEMBL3337659 | 0.98 | LTA4H (0.56) | LTA4HFUCA1KDM1AMAOACD274 | |
| Hydrochloric Acid SCHEMBL3337663 | 0.98 | LTA4H (0.56) | LTA4HFUCA1KDM1AMAOACD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114315609-B | Technological method for preparing cis-2-aminocyclohexanol | 大连双硼医药化工有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023191088-A1 | PLANT-DERIVED ORGANOCATALYST | 協和ファーマケミカル株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-114315609-A | Process for preparing cis-2-aminocyclohexanol | 大连双硼医药化工有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CORREVIO CANADA CORP. (CA) | 2015-11-26 | — | — | US | disclosed |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CORREVIO CANADA CORP. (CA) | 2015-11-26 | — | — | US | disclosed |
| US-9115081-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2015-08-25 | — | — | US | disclosed |
| US-9115081-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2015-08-25 | — | — | US | disclosed |
| EP-2168943-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE TRANS-2-AMINOCYCLOHEXANOL AND INTERMEDIATE OF OPTICALLY ACTIVE TRANS-2-AMINOCYCLOHEXANOL | TORAY FINECHEMICALS CO LTD (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1828099-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | Cardimone Pharma Corporation (CA) | 2007-09-05 | — | — | EP | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2007055180-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE TRANS-2-AMINOCYCLOHEXANOL AND DERIVATIVE THEREOF | TORAY FINE CHEMICALS CO., LTD. (JP) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006088525-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | DDC, PAICS, CYP4F2 | LTA4H 2735/4885FUCA1 4456/4885KDM1A 3301/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | LTA4H 557/4885FUCA1 1726/4885KDM1A 2074/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | LTA4H 557/4885FUCA1 1726/4885KDM1A 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.